Home Blog of Signal Transduction PI3K/Akt/mTOR PI3K Recommendations on the use of azole antifungals in hematology-oncology patients

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

Recommendations on the use of azole antifungals in hematology-oncology patients

The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the administration of some drugs in the azole group, which include voriconazole, posaconazole and isavuconazole, noted for their activity against these pathogens. One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, or any of the vinca alkaloids, are very clear examples of risk, in some cases because their clearance is reduced and in others because of increased risk of QTc prolongation, which is particularly evident when the drug of choice is voriconazole or posaconazole.

 

Comments：

It is true that the administration of antifungal drugs is essential in patients receiving hematology-oncology treatment, particularly for preventing or treating Aspergillus or Mucor infections. However, it is important to note that there is a potential risk of drug interactions when these antifungal drugs are used in combination with certain antineoplastic drugs used to treat hematologic tumors, which can lead to serious complications.

Some examples of antineoplastic drugs that can interact with antifungal drugs include acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, and any of the vinca alkaloids. These drugs can affect the clearance of antifungal drugs, leading to increased levels of these drugs in the bloodstream and potentially causing toxicity. Additionally, some of these drugs can increase the risk of QTc prolongation, which is a potential side effect of some antifungal drugs such as voriconazole or posaconazole.

Therefore, it is crucial to carefully monitor patients receiving these drugs in combination and adjust the dosages accordingly to minimize the risk of drug interactions and potential complications. It is also important to educate patients and healthcare providers about the potential risks and to report any adverse effects or symptoms promptly to their healthcare provider.

Related Products

Cat.No. Product Name Information
S7028 Duvelisib (IPI-145) Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.

Related Targets

PI3K